Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
$1.50
$1.50
$0.64
$15.52
$13.16M3.1815,714 shsN/A
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
$8.20
$7.00
$6.65
$10.71
N/AN/A2,617 shsN/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
$1.26
+8.6%
$1.27
$0.25
$3.40
$9.37M5.8576,432 shs52,426 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
0.00%0.00%0.00%0.00%+17.11%
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
0.00%0.00%+20.59%+13.10%-18.16%
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
-4.13%-29.70%-52.46%+280.20%+36.49%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
N/AN/AN/AN/AN/AN/AN/AN/A
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/AN/AN/AN/AN/AN/AN/AN/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
N/AN/AN/AN/A
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/AN/AN/AN/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
$1.88M7.00N/AN/A$0.18 per share8.33
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/AN/AN/AN/AN/AN/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
$110.75K84.61N/AN/A$0.43 per share2.93

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
-$8.64MN/A0.00N/AN/AN/AN/AN/A
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/AN/A0.00N/AN/AN/AN/AN/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
-$4.65MN/A0.00N/A-4,185.46%-122.57%-97.00%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
N/AN/AN/AN/AN/A
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/AN/AN/AN/AN/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
N/AN/AN/A
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/AN/AN/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
N/A
8.07
7.70

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
0.04%
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
0.65%

Insider Ownership

CompanyInsider Ownership
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
16.00%
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
27.69%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
N/A8.77 million7.37 millionNot Optionable
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
711N/AN/ANot Optionable
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
67.44 million5.38 millionNot Optionable

NXL, 9SP, LOQPF, and AHI Headlines

SourceHeadline
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
finance.yahoo.com - May 9 at 12:19 PM
Nexalin Technology, Inc.: Nexalin Technology Regains Compliance with Nasdaq Continued Listing RequirementsNexalin Technology, Inc.: Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
finanznachrichten.de - April 25 at 6:23 PM
Nexalin Technology Regains Compliance with Nasdaq Continued Listing RequirementsNexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
globenewswire.com - April 25 at 10:44 AM
Nexalin Technology advances in mental health treatmentNexalin Technology advances in mental health treatment
investing.com - April 12 at 12:04 AM
Nexalin Technology CEO Provides Letter to ShareholdersNexalin Technology CEO Provides Letter to Shareholders
globenewswire.com - April 10 at 8:30 AM
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity(TM), a Non-Invasive, Frequency-Based Deep-Brain Stimulation DeviceNexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity(TM), a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
stockhouse.com - April 6 at 9:53 AM
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation DeviceNexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
globenewswire.com - April 4 at 1:00 PM
Nexalin Technologys neurostimulation device shows promise in easing mTBI symptoms in veteransNexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veterans
proactiveinvestors.com - April 2 at 2:41 PM
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory BoardNexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
globenewswire.com - April 2 at 8:30 AM
Nexalin Technology Full Year 2023 Earnings: US$0.63 loss per share (vs US$0.30 loss in FY 2022)Nexalin Technology Full Year 2023 Earnings: US$0.63 loss per share (vs US$0.30 loss in FY 2022)
finance.yahoo.com - March 30 at 10:25 AM
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San DiegoNexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
globenewswire.com - March 28 at 8:30 AM
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s TechnologyNexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
finance.yahoo.com - March 14 at 12:27 PM
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalins TechnologyNexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology
globenewswire.com - March 14 at 8:30 AM
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
globenewswire.com - March 13 at 8:30 AM
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic InsomniaNexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
globenewswire.com - March 6 at 8:30 AM
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation DeviceNexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
finance.yahoo.com - February 8 at 11:10 AM
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) SystemNexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
finance.yahoo.com - January 23 at 11:25 AM
Nexalin Technology Inc NXLNexalin Technology Inc NXL
morningstar.com - January 17 at 12:11 PM
Nexalin Technology Unveils Next-Generation HALO(TM) ClarityNexalin Technology Unveils Next-Generation HALO(TM) Clarity
stockhouse.com - January 11 at 10:35 AM
Nexalin Technology Unveils Next-Generation HALO™ ClarityNexalin Technology Unveils Next-Generation HALO™ Clarity
finance.yahoo.com - January 11 at 10:35 AM
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the ...Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the ...
bakersfield.com - December 18 at 2:04 PM
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant DepressionNexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
finance.yahoo.com - December 18 at 2:04 PM
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain StructuresNexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures
finance.yahoo.com - October 16 at 1:31 PM
Nexalin Technology Inc.Nexalin Technology Inc.
barrons.com - September 14 at 6:37 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Advanced Health Intelligence logo

Advanced Health Intelligence

NASDAQ:AHI
Advanced Health Intelligence Ltd. operates as a mobile application and technology development company in Australia and internationally. It offers biometric health assessments, a multi-step process that employs facial scanning, heart rate measurements, body composition analysis, and cardiovascular fitness tests that evaluates an individual's health. The company also provides FaceScan, process that estimates on heart rate, respiration rate, blood pressure, and other through facial scans; BodyScan, a smart body composition and dimensioning technology that enables user to check and assess body dimensions using a smartphone; and DermaScan, a dermatological scanner. It serves mobile health and telehealth, life and health insurance, wellness, and government sectors. The company was formerly known as Advanced Human Imaging Limited and changed its name to Advanced Health Intelligence Ltd. in December 2022. Advanced Health Intelligence Ltd. was incorporated in 2014 and is based in South Perth, Australia.
accesso Technology Group logo

accesso Technology Group

OTCMKTS:LOQPF
accesso Technology Group plc, together with its subsidiaries, develops technology solutions for the attractions and leisure industry in the United Kingdom, other European countries, Australia, the South Pacific, Asia, the United States, Canada, Mexico, and Central and South America. It operates through Ticketing and Distribution, and Guest Experience segments. The company offers ticketing solutions for theme parks, ski resorts, zoos and aquariums, cultural venues, live entertainment, water parks, fairs and festivals, performing arts, and tours and attractions. It also offers various solutions, such as accesso LoQueue, a virtual queuing solution; the experience engine, an experience management platform; and accesso Passport ticketing suite, which provides daily tickets, season pass, group tickets, meal vouchers, and other services. In addition, the company provides accesso Siriusware, a software solutions providing ticketing and admissions, memberships, reservations, resource scheduling, retail, food service, gift cards, kiosks, and ecommerce services; and accesso ShoWare, a ticketing solutions for box office, kiosk, online, mobile, call center, and social media sales. Further, it operates distribution platform which connects venues and distributors; and point of sale systems. The company was formerly known as Lo-Q plc and changed its name to accesso Technology Group plc in November 2013. accesso Technology Group plc was incorporated in 2000 and is based in Twyford, the United Kingdom.
Nexalin Technology logo

Nexalin Technology

NASDAQ:NXL
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. In addition, it designs and develops Generation 2 and Generation 3, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, Alzheimer's disease, and dementia. The company is based in Houston, Texas.